3 Horrendous Health-Care Stocks This Week: VIVUS, Inc. (VVUS), Accretive Health, Inc. (AH), Dynavax Technologies Corporation (DVAX)

Page 2 of 2

Sales for the company’s weight loss pill, Qsysmia, haven’t taken off as hoped for. One of the key problems thus far has been VIVUS’ sales channel, which is currently limited to mail-order pharmacies. There have been some reimbursement hurdles as well, although insurer Aetna Inc. (NYSE:AET) and pharmacy benefits manager Express Scripts Holding Company (NASDAQ:ESRX) both have announced they would cover Qsymia.

Sequestered
Which of the three horrendous stocks of the past week should definitely be sequestered from investors’ portfolios? I’d have to go with Dynavax as the one facing the toughest battle.

Accretive’s problems are self-inflected, and VIVUS does at least have two products already approved by the FDA. Dynavax faces challenges in large part beyond its control. That’s not to way that Dynavax doesn’t have the possibility of coming back. It does. But, like our bloated federal government, we have to cut somewhere.

The article 3 Horrendous Health-Care Stocks This Week originally appeared on Fool.com and is written by Keith Speights.

Fool contributor Keith Speights has no position in any stocks mentioned. The Motley Fool recommends Express Scripts. The Motley Fool owns shares of Express Scripts.

Copyright © 1995 – 2013 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.

Page 2 of 2